THE Pharmaceutical Benefits Advisory Committee (PBAC) has recommended adding the new 9-valent Gardasil-9 human papilloma virus vaccine from CSL's Seqirus to the National Health Immunisation Program (NIP) -- Designated Vaccines, from its Jul meeting Public Summary Document release (PD 22 Aug 17).
Other recommendations include the PBAC acceptance of a Ridaura (oral gold) capsule to replace the tablet from 01 Jul due to supply issues and decisions around 31 other products - see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Oct 17